IL6 and congenital rubella syndrome: Additionally, removal of genes encoding cytokines that drive neurotoxicity and cytokine release syndrome (CRS) such as GM-CSF [93] and IL-6 [94] with CRISPR-Cas9 editing has the potential to produce an optimally potent and durably persistent cell product, while reducing adverse events associated with aberrant cytokine production.